The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Hydroxychloroquine for COVID-19 Fails Another Test

Hydroxychloroquine for COVID-19 Fails Another Test

May 12, 2020 • By Gene Emery

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—The malaria treatment repeatedly championed by U.S. President Donald Trump as a game changer in the fight against the novel coronavirus has again failed to show a benefit in patients hospitalized with COVID-19, according to a recent study.

You Might Also Like
  • Hydroxychloroquine Tied to Increased Risk of Death in COVID-19 Patients
  • Hydroxychloroquine Combination Risky for Cancer Patients with COVID-19
  • U.S. FDA Warns Against Using Hydroxychloroquine for COVID-19

Although the study published in The New England Journal of Medicine had certain limitations, doctors report that the use of hydroxychloroquine (HCQ) lessened neither the need for mechanical ventilation nor the risk of death.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“We didn’t see any association between getting this medicine and the chance of dying or being intubated,” lead researcher Dr. Neil Schluger tells Reuters in a telephone interview. “The patients who got the drug didn’t seem to do any better.”

Among patients given HCQ, 32.3% ended up needing a ventilator or dying, compared with 14.9% of patients who were not given the drug.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

But doctors were more likely to give HCQ to sicker patients, so researchers at New York-Presbyterian Hospital and Columbia University Irving Medical Center adjusted the rates to account for that. They concluded that the drug may not have hurt patients, but it clearly did not help.

Decades old HCQ, which is also used to treat lupus and rheumatoid arthritis, also showed no benefit when combined with the antibiotic azithromycin, Schluger’s team reported. Azithromycin alone also showed no benefit.

Last month, doctors at the U.S. Department of Veterans Affairs reported that HCQ did not help COVID-19 patients and might pose a higher risk of death.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

That analysis of medical records showed a death rate of 28% when the drug was given in addition to standard treatments, compared to 11% with standard care alone.

In the latest study, 811 patients got HCQ and 565 did not.

Because they were not randomly assigned to receive HCQ or a placebo, “the study should not be taken to rule out either benefit or harm” for the drug, researchers said. Randomized trials, the gold standard for tests of new therapies, should continue, they added.

But for now, “the guidance in our hospital has changed so we don’t recommend giving HCQ to hospitalized patients,” says Dr. Schluger, chief of the division of pulmonary, allergy and critical care medicine at Irving.

Smaller studies, including one done in China, had suggested HCQ might be useful, “but these were tiny studies and not of good quality. People seized on them because patients were dying,” he says.

There are currently no approved treatments for COVID-19, although Gilead Sciences Inc’s experimental antiviral drug remdesivir last week receive emergency use authorization from U.S. regulators.


Reference

  1. Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with COVID-19. N Engl J Med. 2020 May 7. [Epub ahead of print]

Pages: 1 2 | Multi-Page

Filed Under: Drug Updates Tagged With: coronavirus, COVID-19, HCQ, Hydroxychloroquine (HCQ)

You Might Also Like:
  • Hydroxychloroquine Tied to Increased Risk of Death in COVID-19 Patients
  • Hydroxychloroquine Combination Risky for Cancer Patients with COVID-19
  • U.S. FDA Warns Against Using Hydroxychloroquine for COVID-19
  • Tocilizumab Fails to Help COVID-19 Patients in Italian Study

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.